Loading
Life sciences · Journal article
Frontiers in Genetics · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Robotic bronchoscopy is increasingly used to sample peripheral pulmonary lesions as lung cancer screening detects more small, distal, subsolid and ground-glass nodules. Most evidence has assessed the technology by diagnostic yield and safety, but these endpoints only partly capture clinical value. In early lung cancer care, the relevant question is whether bronchoscopy provides information that is sufficient for diagnosis, staging, molecular profiling and treatment-ready decision-making. This state-of-the-art review examines robotic bronchoscopy as a potential diagnosis-to-treatment platform rather than an isolated navigation device. We summarise evidence on distal airway access, procedural stability, CT-to-body divergence, tool-in-lesion confirmation, cone-beam CT, mobile cone-beam CT and radial endobronchial ultrasound. We also discuss tissue stewardship, rapid on-site evaluation, cell block preparation, next-generation sequencing, PD-L1 testing and same-session endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and, when appropriate, endoscopic ultrasound with bronchoscope-guided fine-needle aspiration (EUS-B-FNA) as determinants of molecular adequacy and clinical actionability. We propose clinically actionable yield as a pragmatic, complementary, and currently unvalidated reporting construct linking lesion access, confirmed targeting, pathological diagnosis, molecular adequacy, staging completeness, and management decisions. For prospective evaluation, Level 5 (treatment decision informed or changed) should be assessed within 30 days after the index bronchoscopic procedure or before definitive therapy, whichever occurs first. Bronchoscopic ablation is considered as a future therapeutic extension, but current evidence remains early and does not establish equivalence with surgery, stereotactic body radiotherapy or percutaneous ablation. Future studies should evaluate decision-centred and patient-centred endpoints, including molecular-testing success, repeat biopsy avoidance, time to treatment, local control, pulmonary function, quality of life and cost-effectiveness.